EVALUATION OF SERUM γ-GLUTAMYL TRANSFERASE AND ITS ASSOCIATION WITH HIGH SENSITIVITY C-REACTIVE PROTEIN AND INSULIN LEVELS IN THE PATIENTS WITH METABOLIC SYNDROME

  • R. Dharuni SAPTHAGIRI INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE, BANGALORE, INDIA
  • B. V. Maruthi Prasad BANGALORE MEDICAL COLLEGE AND RESEARCH INSTITUTE, BANGALORE, INDIA
  • H. L. Vishwanth BANGALORE MEDICAL COLLEGE AND RESEARCH INSTITUTE, BANGALORE, INDIA
Keywords: metabolic syndrome, gamma-glutamyl transferase, high sensitivity C-reactive protein, HOMA-IR

Abstract

Background. Metabolic syndrome (MS), a collection of cardiovascular risk factors, is a major worldwide public health problem. The gathered data prove that serum gamma-glutamyl transferase (γGT) activity is a true marker of atherosclerotic cardiovascular disease (CVD) and is of a prognostic importance as well as the high-sensitivity C-reactive protein (hs-CRP).

Objectives. In the study, we sought to evaluate serum γGT activity, hs-CRP and insulin resistance in patients with MS.

Methods. The study involved 50 persons with metabolic syndrome and 50 healthy age and sex matched controls. Fasting serum samples of all participants were investigated for γGT, hs-CRP, insulin, blood glucose, lipid profile and liver function tests. Anthropometric measurements and BMI were also calculated

Results. In that case 50% showed significantly high γGT compared to the controls, 30% proved increased hs-CRP levels above >0.5 mmol/L, whereas 94% of the controls were within the reference range. 74% of cases revealed the presence of insulin resistance while 32% of the controls showed insulin resistance. High γGT levels were also observed in that case with deranged lipids levels and high BMI.

Conclusions. The study suggests that the patients with MS have a higher serum γGT activity. This study also proves that hs-CRP and HOMA-IR, which are independent risk factors of CVD, are also associated with MS. The correlation between γGT and the components of MS are also found significant compared to hs-CRP. Thus, γGT can be considered as an inexpensive and authentic predictor of MS, which can be a manifestation of CVD in near future.

Author Biographies

R. Dharuni, SAPTHAGIRI INSTITUTE OF MEDICAL SCIENCES AND RESEARCH CENTRE, BANGALORE, INDIA

Assistant Professor, Department of Biochemistry, Sapthagiri Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India.

ORCID 0000-0002-3543-2810

B. V. Maruthi Prasad, BANGALORE MEDICAL COLLEGE AND RESEARCH INSTITUTE, BANGALORE, INDIA

Professor, Bangalore Medical College and Research Institute, Bangalore, Karnataka, India.

ORCID 0000-0002-2951-9151

H. L. Vishwanth, BANGALORE MEDICAL COLLEGE AND RESEARCH INSTITUTE, BANGALORE, INDIA

Professor and Head, Bangalore Medical College and Research Institute,

Bangalore, Karnataka, India.

ORCID 0000-0001-7331-4308

References

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: A joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; International atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640-5.

Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56:1113-32.

Nemesánszky E, Lott JA. Gamma-gluta­myltransferase and its isoenzymes: Progress and problems. Clin Chem. 1985;31:797-803.

https://www.ncbi.nlm.nih.gov/pubmed/2859933

André P, Balkau B, Vol S, Charles MA, Eschwè­ge E, DESIR Study Group, et al. Gamma-glutamyl­transferase activity and development of the meta_bolic syndrome (International diabetes federation definition) in middle-aged men and women: Data from the epidemiological study on the insulin resistance syndrome (DESIR) cohort. Diabetes Care. 2007;30:2355-61.

Targher G. Elevated serum gamma-gluta­myltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardio­vascular events, chronic kidney disease and cancer - A narrative review. Clin Chem Lab Med. 2010;48:147-57.

Turgut O, Tandogan I. Gamma-glutamyl­transferase to determine cardiovascular risk: Shifting the paradigm forward. J Atheroscler Thromb. 2011;18:177-81.

Cho NH, Jang HC, Choi SH, Kim HR, Lee HK, Chan JC, et al. Abnormal liver function test predicts type 2 diabetes: A community-based prospective study. Diabetes Care. 2007;30:2566-8.

Ford ES, Schulze MB, Bergmann MM, Thamer C, Joost HG, Boeing H, et al. Liver enzymes and incident diabetes: Findings from the European prospective investigation into cancer and nutrition (EPIC)-potsdam study. Diabetes Care. 2008;31:1138-43.

Sato KK, Hayashi T, Nakamura Y, Harita N, Yoneda T, Endo G, et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: The Kansai healthcare study. Diabetes Care. 2008;31:1230-6.

Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the deve­lopment of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30.

Grundy SM, Cleeman JI, Daniels SR, Dona­to KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An Ame­rican heart association/National heart, lung, and blood institute scientific statement: Executive sum­mary. Crit Pathw Cardiol. 2005;4:198-203

Tracy RP. Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl. 2003;134:10-7.

https://www.ncbi.nlm.nih.gov/pub­med/12793593

González AS, Guerrero DB, Soto MB, Díaz SP, Martinez-Olmos M, Vidal O, et al. Metabolic syndrome, insulin resistance and the inflam­mation markers C-reactive protein and ferritin. Eur J Clin Nutr. 2006;60:802-9.

Wei D, Chen T, Gao Y, Tian H. Serum gamma-glutamyltransferase and ferritin are related to insulin resistance: A Population-based study. Clin Lab. 2015;61:1157-61.

Emdin M, Passino C, Michelassi C, Donato L, Pompella A, Paolicchi A, et al. Additive prognostic value of gamma-glutamyltransferase in coronary artery disease. Int J Cardiol. 2009;136:80-5.

Du G, Song Z, Zhang Q. Gamma-glu­tamyltransferase is associated with cardiovas­cular and all-cause mortality: A meta-analysis of prospective cohort studies. Prev Med. 2013;57:31-7.

Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: A systematic review and dose-response meta-analysis. Int J Clin Pract. 2015;69:136-44.

Relationship between serum gamma-glutamyltransferase activity and cardiometabolic risk factors in metabolic syndrome. J Family Med Prim Care. 2018;7(2):430-434.

Liu CF, Gu YT, Wang HY, Fang NY. Gamma-glutamyltransferase level and risk of hypertension: A systematic review and meta-analysis. PLoS One. 2012;7:e48878

Stranges S, Trevisan M, Dorn JM, Dmo­chowski J, Donahue RP. Body fat distribution, liver enzymes, and risk of hypertension: Evidence from the western New York study. Hypertension. 2005;46:1186-93.

Ortega E, Koska J, Salbe AD, Tataran­ni PA, Bunt JC. Related articles, links serum gamma-glutamyl transpeptidase is a determi­nant of insulin resistance independently of adiposity in Pima Indian children. J Clin Endocrinol Metab 2006;91:1419-22.

Aksakal E, Tanboga IH, Kurt M, Kaygın MA, Kaya A, Isik T, et al. The relation of serum gamma-glutamyl transferase levels with coro­nary lesion complexity and long-term outcome in patients with stable coronary artery disease. Atherosclerosis 2012;221:596-601

Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardio­vascular risk? Circulation 2004; 109: 2818-2825.

Lee DH, Jacobs DR Jr. Association between serum gammaglutamyltransferase and C-reactive protein. Atherosclerosis 2005; 178: 327-330.

Published
2019-07-11
How to Cite
Dharuni, R., Maruthi Prasad, B. V., & Vishwanth, H. L. (2019). EVALUATION OF SERUM γ-GLUTAMYL TRANSFERASE AND ITS ASSOCIATION WITH HIGH SENSITIVITY C-REACTIVE PROTEIN AND INSULIN LEVELS IN THE PATIENTS WITH METABOLIC SYNDROME. International Journal of Medicine and Medical Research, 5(1), 10-16. https://doi.org/10.11603/ijmmr.2413-6077.2019.1.9693